Prognostic value of 5-hydroxyindoleacetic acid (5-HIAA)

Urinary 5-HIAA, the primary metabolite of serotonin, has both diagnostic and prognostic value in NETs associated with carcinoid syndrome.1-3 5-HIAA is measured by high-precision liquid chromatography in a 24-hour urine sample.4

Elevated levels of 5-HIAA have been associated with poor outcomes5 and the development of carcinoid heart disease.6 Reductions in 5-HIAA are correlated with relief of carcinoid symptoms and disease stabilization.7

Considerations when ordering 5-HIAA testing

5-HIAA is only elevated in NETs/metastases that secrete serotonin. It may not be a useful marker in other NETs.1

5-HIAA may be increased by ingestion of foods high in serotonin, such as avocados, bananas, pineapples, walnuts, and kiwifruit.2 Certain medications, including guaifenesin, acetaminophen, salicylates, and L-dopa, may also affect 5-HIAA. Patients should be instructed to avoid these foods and medications before and during urine collection.2

Diagnosing NETs

Multidisciplinary Approach

Many of the same tools that can be used to monitor NETs can be helpful in diagnosing them.

MORE
 

A Multidisciplinary Approach

Multidisciplinary Approach

"...the many treatments that are out there...really involve more than one decision by one specialty. It really involves
an integration."

DISCOVER
 

Managing from a nurse's perspective

nurse's perspective

Tips to educate, engage, and empower your patients.

LEARN
 
1. Mamikunian G, Vinik AI, O'Dorisio TM, Woltering EA, Go VLW. Diagnosing and treating gastroenteropancreatic tumors, including ICD-9 codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 4th ed. Inglewood, CA: Inter Science Institute; 2009:1-43.
2. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1559-1574.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.
4. Ferolla P, Faggiano A, Mansueto G, et al. The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest. 2008;31(3):277-286.
5. Formica V, Wotherspoon A, Cunningham D, et al. The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract. Br J Cancer. 2007;96(8):1178-1182.
6. Møller JE, Connolly HM, Rubin J, Seward JB, Modesto K, Pellikka PA. Factors associated with progression of carcinoid heart disease. N Engl J Med. 2003;348(11):1005-1015.
7. Jensen EH, Kvols L, McLoughlin JM, et al. Biomarkers predict outcomes following cytoreductive surgery for hepatic metastases from functional carcinoid tumors. Ann Surg Oncol. 2007;14(2):780-785.
1. Mamikunian G, Vinik AI, O'Dorisio TM, Woltering EA, Go VLW. Diagnosing and treating gastroenteropancreatic tumors, including ICD-9 codes. In: Neuroendocrine Tumors: A Comprehensive Guide to Diagnosis and Management. 4th ed. Inglewood, CA: Inter Science Institute; 2009:1-43.
2. Jensen RT, Doherty GM. Carcinoid tumors and the carcinoid syndrome. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles & Practice of Oncology. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005:1559-1574.
3. Rorstad O. Prognostic indicators for carcinoid neuroendocrine tumors of the gastrointestinal tract. J Surg Oncol. 2005;89(3):151-160.